DOI QR코드

DOI QR Code

Early Detection and Gemcitabine/Cisplatin Combination Positively Effect Survival in Sarcomatoid Carcinoma of the Urinary Bladder

  • Baseskioglu, Barbaros (Department of Urology, ESOGU Medical Faculty) ;
  • Duman, Berna Bozkurt (Department of Medical Oncology, Cukurova University Medical Faculty) ;
  • Kara, I. Oguz (Department of Medical Oncology, Cukurova University Medical Faculty) ;
  • Can, Cavit (Department of Urology, ESOGU Medical Faculty) ;
  • Yildirim, Mustafa (Antalya Education and Research Hospital) ;
  • Acikalin, Mustafa (Department of Pathology, ESOGU Medical Faculty)
  • 발행 : 2012.11.30

초록

Background and Objectives: This study aimed to present the clinicopathological characteristics and treatment of patients with bladder carcinoma with sarcomatoid differentiation at our institution. Methods: Between 1995-2009, 950 patients were followed-up for bladder carcinoma. Among them, 14 patients with sarcomatoid carcinoma were retrospectively reviewed, and their clinical, pathological features and treatment were recorded. Results: Median age of the patients was 65 years (range: 41-86 years), 12 (86%) being male and 2 (14%) female. All the patients presented with hematuria and 11 (88%) had a history of smoking. The tumor growth pattern was solid in 10 patients, papillary in 2, and mixed in 2. In all, 5 of the patients had urothelial carcinoma with sarcomatoid differentiation and 9 were diagnosed with sarcomatoid carcinoma. Five patients underwent radical cystectomy with ileal conduit surgery, 2 patients refused cystectomy, and 8 patients underwent re-TUR. Following diagnosis, 12 of the patients died in mean 10.7 months (range: 1-48 months). Conclusion: Urothelial carcinomas with sarcomatoid features are aggressive and are usually at advanced stage at the time of diagnosis. The outcomes of multimodal treatment are not satisfactory. Significant findings of the present study are that early diagnosis positively affect survival and that gemcitabine and cisplatin in combination can positively affect survival.

키워드

참고문헌

  1. Doghri R, Sellami R, Driss M, et al (2012). Sarcomatoid carcinoma of the urinary bladder. Tunis Med, 90, 183-4.
  2. Eble JN, Sauter G, Epstein JI, Sesterhenn I (eds): "Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs." IARC Press: Lyon, 2004.
  3. Escudier B, Pluzanska A, Koralewski P et al (2007). AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370, 2103-11. https://doi.org/10.1016/S0140-6736(07)61904-7
  4. Froehner M, Gaertner HJ, Manseck A, Wirth MP (2001). Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man. Urology, 58, 799.
  5. Ikegami H, Iwasaki H, Ohjimi Y, et al (2000). Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients. Hum Pathol, 31, 332-40. https://doi.org/10.1016/S0046-8177(00)80247-6
  6. Jemal A, Siegel R, Xu J, Ward E (2009). Cancer Statistics, 2010. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  7. Jue Wanga J, Gillaspiea C, Kunadharajua R, Talmon GA, Enke C (2011). Sarcomatoid urothelial carcinoma: a single cancer center experience. World J Oncol, 2, 175-80
  8. Lopez-Beltran A, Pacelli A, Rothenberg HJ, et al (1998). Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol, 159, 1497-503. https://doi.org/10.1097/00005392-199805000-00023
  9. Mansure JJ, Nassim R, Chevalier S, et al (2009). Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther, 8, 2339-47.
  10. Nimeh T, Kuang W, Levin HS, Klein EA (2002). Sarcomatoid transitional cell carcinoma of bladder managed with transurethral resection alone. J Urol, 167, 641-2. https://doi.org/10.1016/S0022-5347(01)69104-3
  11. Nishikawa R, Fujimura M, Endo Y, et al (2011). A case of carcinosarcoma of the urinary bladder). Hinyokika Kiyo, 57, 199-202.
  12. Singh NG, Mannan AA, Kahvic M, Sara YA (2011). Sarcomatoid carcinoma of the urinary bladder: a report of two cases. Indian J Pathol Microbiol, 54, 400-1. https://doi.org/10.4103/0377-4929.81635
  13. Stamatiou K, Galariotis N, Michailidis I, et al (2010). Sarcomatoid carcinoma of the urinary bladder: a clinicopathological study of 4 cases and a review of the literature. Korean J Urol, 51, 724-8. https://doi.org/10.4111/kju.2010.51.10.724
  14. Sung MT, Wang M, MacLennan G, et al (2007). Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J Pathol, 211, 420-30. https://doi.org/10.1002/path.2129
  15. Tickoo SK, Milowsky MI, Dhar N, et al (2010). Hypoxiainducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int.
  16. Torenbeek R, Blomjous CE, de Bruin PC, et al (1994). Sarcomatoid carcinoma of the urinary bladder: clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol, 18, 241-9. https://doi.org/10.1097/00000478-199403000-00003
  17. Wang J, Wang FW, LaGrange CA, et al (2010). Clinical features of sarcomatoid (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma, 2, 454792.
  18. Young RH (1987). Carcinosarcoma of the urinary bladder. Cancer, 59, 1333-9. https://doi.org/10.1002/1097-0142(19870401)59:7<1333::AID-CNCR2820590717>3.0.CO;2-N

피인용 문헌

  1. A Case of Early Stage Bladder Carcinosarcoma in Late Recurrence of Urothelial Carcinoma after Transurethral Resection vol.2018, pp.2090-6978, 2018, https://doi.org/10.1155/2018/1405108